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The immunosuppressive function of regulatory B
cells has been shown in several murine models of
chronic inflammation, including collagen-induced
arthritis, inflammatory bowel disease, and experi-
mental autoimmune encephalomyelitis. Despite
interest in these cells, their relevance to the mainte-
nance of peripheral tolerance in humans remains
elusive. Here, we demonstrate that human CD19+
CD24hiCD38hi B cells possessed regulatory capacity.
After CD40 stimulation, CD19+CD24hiCD38hi B cells
suppressed the differentiation of T helper 1 cells,
partially via the provision of interleukin-10 (IL-10),
but not transforming growth factor-b (TGF-b), and
their suppressive capacity was reversed by the addi-
tion of CD80 and CD86 mAbs. In addition,
CD19+CD24hiCD38hi SLE B cells isolated from the
peripheral blood of systemic lupus erythematosus
(SLE) patients were refractory to further CD40 stimu-
lation, produced less IL-10, and lacked the suppres-
sive capacity of their healthy counterparts. Altered
cellular function within this compartment may impact
effector immune responses in SLE and other autoim-
mune disorders.
INTRODUCTION
Regulatory cells are important for maintenance of immunological
homeostasis and self-tolerance (Hayday and Tigelaar, 2003;
Mauri and Ehrenstein, 2008; Van Parijs and Abbas, 1998). In
the majority of autoimmune diseases, B cells are generally
considered to be pathogenic because of their capacity to
secrete autoantibodies (Shlomchik et al., 1994; Yanaba et al.,
2008b). However, it has emerged that specific subsets of B cells
downregulate immune responses in mice, and their absence or
loss results in exacerbated autoimmune responses (Fillatreau
et al., 2002; Mauri et al., 2003; Mizoguchi et al., 1997). Different
B cell subsets have been ascribed with regulatory function, such
as CD5+B-1a cells (Carroll and Prodeus, 1998; Silverman et al.,
2008), CD19hiCD1dhiCD5+ B cells (Matsushita et al., 2008;Yanaba et al., 2008a), or marginal zone (MZ) B cells (Gray
et al., 2007; Lenert et al., 2005). We recently demonstrated that
interleukin-10 (IL-10)+ B cells in a collagen-induced arthritis
(CIA) model are found within the immature transitional two-
marginal zone precursor B cell subset (T2-MZP) and display a
CD19+CD21hiCD23hiCD24hiCD1dhi phenotype. Adoptive trans-
fer of T2-MZP B cells from naive or convalescent mice prevented
recipient syngeneic DBA/1 mice from developing arthritis (Evans
et al., 2007). We have also identified regulatory B (Breg) cells with
a similar phenotype (T2-like) in MRL/lpr mice, which spontane-
ously develop lupus-like disease, and demonstrated that they
can be enriched upon short-term in vitro culture with agonistic
CD40 monoclonal antibody (mAb) (Blair et al., 2009). Functional
analysis of murine Breg cells showed that this population prefer-
entially produce IL-10, but can also release transforming growth
factor-b (TGF-b), interferon-g (IFN-g), and interleukin-12 (IL-12)
(Blair et al., 2009; Evans et al., 2007; Fillatreau et al., 2002;
Mizoguchi et al., 2002; Sugimoto et al., 2007; Tian et al., 2001).
Detailed characterization in vitro and in vivo revealed that their
suppressive capacity is mediated by the provision of IL-10 and
by direct contact with CD4+ T cells (Mauri et al., 2003) (Mizoguchi
et al., 2002).
CD40 signaling is pivotal for the generation and function of
Breg cells in experimental autoimmune encephalomyelitis
(EAE), CIA, and lupus and inflammatory bowel disease models
(Fillatreau et al., 2002; Mauri et al., 2003; Mizoguchi et al.,
2000). In CIA, stimulation of B cells with an agonistic CD40
mAb gives rise to a population of B cells with potent suppres-
sive capacity both in vivo and in vitro (Mauri et al., 2003).
Chimeric mice reconstituted with CD40-deficient B cells, but
having otherwise normal immune systems, are unable to
recover from EAE because of the inability of the B cells to
produce IL-10 (Fillatreau et al., 2002). Similarly, CD40-deficient
B cells are unable to protect colitis prone TCRa knockout (KO)
mice from developing inflammatory colitis, unlike wild-type B
cells (Mizoguchi et al., 1997). Engagement of CD40 on human
B cells leads preferentially, as in mice, to the production of IL-
10 (Duddy et al., 2004). However, in contrast to the murine
studies, there is a paucity of data regarding any potential
role for an equivalent regulatory B lymphocyte population
either in healthy individuals or in patients with autoimmune
disease (Duddy et al., 2007) (Correale et al., 2008). In this
study, we examined the functional regulatory properties of
peripheral blood (PB)-derived human B cell subsets fromImmunity 32, 129–140, January 29, 2010 ª2010 Elsevier Inc. 129
Figure 1. CD19+CD24hi CD38hi B Cells from Healthy Individuals Suppress T Helper Cell Differentiation
(A) PBMCs were stained with CD19, CD24, and CD38 and gated as previously shown (Carsetti et al., 2004). Representative histograms showing the surface
expression of IgM, IgD, CD5, CD10, CD27, and CD1d of CD19+CD24hiCD38hi, CD19+CD24+CD38, and CD19+CD24intCD38int B cell subsets. Results are
representative of 14 different healthy controls.
(B) CD1d and CD5 expression on CD19+ B cells was assessed by immunofluorescence as previously shown in mice (Matsushita et al., 2008; Yanaba et al., 2008a).
(C) Representative dot plot showing CD19+CD1dhiCD5+ B cells (black dots) overlaid on a plot depicting CD24 and CD38 expression by total CD19+ B cells
(gray dots).
(D) Flow cytometry-sorted CD19+CD24hiCD38hi, CD19+CD24+CD38, and CD19+CD24intCD38int DAPI B cell subsets from healthy individuals were cultured
1:1 with autologous magnetic-bead-purified CD4+ CD25 T cells for 72 hr with 0.5 mg/ml plate-bound CD3 mAb. PMA+iono was added in the last 6 hr of culture.
Representative histograms for 1 out of 14 individuals, showing the frequencies of CD4+IFN-g+ and CD4+TNF-a+ are shown.
(E) Bar graphs show percentage inhibition of the frequency of CD4+IFN-g+ and CD4+TNF-a+ T cells after coculture with specified B cells’ subset. Cumulative
results expressed as mean ± SE (standard error of the mean). The results were compared with two-tailed t test analysis (CD4:CD24hiCD38hi versus other groups),
*p < 0.01. One out three independent experiments using a minimum of six samples for each group is shown.
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cells from patients with systemic lupus erythematosus (SLE)
who are known to have profound alterations in the regulation
of immune responses (Grammer and Lipsky, 2003; Rahman
and Isenberg, 2008; Suen et al., 2009).
Here, we describe that CD19+CD24hiCD38hi B cells isolated
from human PB inhibited the differentiation of T helper 1 (Th1)
cells in vitro. This suppressive effect was mediated by a combi-
nation of the release of IL-10 and by the engagement of CD80
and CD86. Furthermore, we report that the same population of
B cells isolated from the PB of SLE patients lacked equivalent
regulatory capacity.RESULTS
CD19+CD24hiCD38hi B Cells Inhibit Proinflammatory
Cytokine Production by CD4+ T Cells
Analysis of 14 healthy donors revealed, as has been previously
shown, three distinct B cell populations in the PB: CD19+
CD38hiCD24hi B cells (a population that includes immature B
cells), CD19+CD38intCD24int B cells (primarily mature B cells),
and CD19+CD24hiCD38 B cells (primarily memory B cells)
(Carsetti et al., 2004; Sims et al., 2005). Further phenotypical
identification confirmed that the majority of CD19+CD38hiCD24hi
B cells were also IgMhiIgDhiCD5+CD10+CD20+CD27CD1dhi;
whereas CD19+CD38intCD24int B cells were IgMintIgD+
CD5CD10CD20+CD27CD1d+. CD19+CD24hiCD38 B cells
were CD5CD10CD27+CD1d+ and can have either an
IgM+IgD+ or IgMIgD phenotype (Figure 1A). Interestingly, the
majority of the CD19+CD5+CD1dhiB cells (71%), previously re-
ported to be regulatory in experimental models of inflammation
(Matsushita et al., 2008; Yanaba et al., 2008a), are contained
within the CD24hiCD38hi B cell subset (Figures 1B and 1C).
To assess the functional regulatory properties of PB B cells,
we sorted CD19+CD24hiCD38hi, CD19+CD24hiCD38, or
CD19+CD24intCD38intDAPI B cells by flow cytometry from
healthy donors and cultured them 1:1 with autologous
magnetic-bead purified CD4+CD25 T cells. The gating criteria
and postsort purity of B cell subsets are shown respectively in
Figure 1A and Figure S1A available online. Cultures were stimu-
lated with CD3 mAb, and the frequencies of CD4+IFN-g+ and
CD4+ tumor necrosis factor-a (TNF-a)+ T cells were assessed
by flow cytometry. CD4+ T cells cultured with either CD19+
CD24intCD38int or CD19+CD24hiCD38 B cells produced equiv-
alent amounts of proinflammatory cytokines to cultures contain-
ing CD4+ T cells alone. In contrast, culture of CD4+ T cells with
CD19+CD24hiCD38hi B cells significantly suppressed the
frequencies of CD4+IFN-g+ and CD4+TNF-a+ T cells (Figures
1D and 1E). This inhibitory effect was cell dose dependent
(Figure 1F). CD19+CD24hiCD38hi B cells were, at least under
these experimental conditions, unable to suppress Th17 cell
differentiation (Figure S1B).(F) CD19+CD24hiCD38hi B cells dose dependently inhibit proinflammatory cytokin
T cells were cultured with different concentrations of flow cytometry-sorted CD19
measured after 72 hr in vitro stimulation with CD3 mAb (0.5 mg/ml) by intracellular
with the two-tailed t test analysis.IL-10+ B Cells Are Enriched within
the CD19+CD24hiCD38hi B Cell Subset
We next determined whether IL-10-producing B cells were
enriched within any of the previously described B cell subset(s).
CD19+CD24hiCD38hi, CD19+CD24hiCD38, and CD19+CD24int
CD38int B cells were sorted by flow cytometry from healthy
donors, cultured with Chinese hamster ovary (CHO) cells that
had been transfected with CD154 (CHO-CD154) or with control
CHO cells, and stimulated briefly with phorbol myristate acetate
(PMA) and ionomycin (PMA+iono). Intracellular staining for IL-10
demonstrated that a significantly higher percentage of
CD19+CD24hiCD38hi B cells were IL-10+ compared with
CD19+CD24hiCD38 and CD19+CD24intCD38int B cells (Figures
2A and 2B). To complement the results obtained by intracellular
staining, we measured IL-10 production by ELISA in the super-
natants derived from the aforementioned experiments prior to
stimulation with PMA+iono. The results in Figure 2C demonstrate
that, upon CD40 engagement, there were higher amounts of
IL-10 in the supernatants of cultured CD19+CD24hiCD38hi B cells
compared to CD19+CD24hiCD38 or CD19+CD24intCD38int
B cells. Moreover, after culture of healthy PBMCs with
CHO-CD154 cells and stimulation with PMA+iono, the majority
of IL-10-expressing B cells were enriched within the
CD19+CD24hiCD38hi gating. In addition, the CD24hiCD38hi B
cells defined the brightest IL-10-stained cells after CD40
engagement followed by PMA+iono stimulation (Figures 2D
and 2E and Figure S2). Although back-calculation of the absolute
numbers of IL-10+ B cells suggest that there are similar numbers
of IL-10+CD24hiCD38hi and IL-10+CD19+CD24intCD38int B cells
present in the PB (Figure S3A), CD19+CD24intCD38int B cells
still fail to suppress CD4+ T cell activation even at a ratio of five
B cells to one T cell (Figure S3B). Irradiated CHO cells cultured
alone made no detectable IL-10 measured by ELISA. In addition
there was negligible IL-10 production by any B cell subset in
response to IgM (Fab’)2, or IgM (Fab’)2 in combination with
CHO-CD154 cells, measured by ELISA or by intracellular stain-
ing [stimulation with IgM (Fab’)2, or IgM (Fab’)2 in combination
with CHO-CD154 cells was followed by PMA+iono] (data not
shown).
In vivo, activated T cells may be the cells that provide the
necessary CD40 stimulation to CD19+CD24hiCD38hi B cells for
the production of IL-10. We hypothesized that the upregulation
of CD154 in response to CD3 mAb stimulation might be pivotal
for the efficient generation of IL-10+ CD19+CD24hiCD38hi B cells
with regulatory capacity (Figure 2F). To assess this possibility,
we cocultured flow cytometry-sorted CD19+CD24hiCD38hi
B cells with magnetic bead-purified CD4+CD25 T cells and
stimulated them with CD3 mAb alone or with CD3 mAb in the
presence of neutralizing CD154 mAb. Consistent with this idea,
B cells cultured with unstimulated T cells did not produce any
IL-10, whereas coculture with T cells activated with CD3 mAb,
which upregulated CD154 expression, led to the generation of
IL-10-expressing B cells (Figure 2G). The production of IL-10e production by CD4+T cells. Negatively magnetic-bead purified CD4+ CD25
+CD24hiCD38hi B cells from the same healthy donors. Cytokine production was
staining. Graphs show mean ± SE. Data were compared by statistical analysis
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Figure 2. Ex Vivo Identification of Human IL-10-Producing B Cells
CD19+CD24hiCD38hi, CD19+CD24+CD38, and CD19+CD24intCD38int DAPI
B cells were flow cytometry sorted from the PB of healthy individuals and
were stimulated for 72hrs with CHO-CD154, control CHO cells. PMA+iono
were added for the last 6hrs of culture. CD19+IL-10+ B cells were measured
by intracellular cytokine staining. IL-10 expression on CD19+ B cells was
assessed relative to an isotype matched control mAb.
(A) Representative dot plot for one individual showing the frequency of IL-10
produced by different flow cytometry sorted B cell subsets.
(B) Cumulative results from three independent experiments with five samples
per group. Bar graphs indicate mean ± SE percentages of CD19+CD24hiCD38hi,
CD19+CD24+CD38, and CD19+CD24intCD38int B cells that produced IL-10.
(C) Supernatants from purified B cell subsets, cultured as in (A), were tested
for the presence of IL-10 prior to stimulation with PMA+iono by ELISA. Data
are shown as mean ± SE. Data were compared by statistical analysis with
the two-tailed t test analysis (CHO-CD154 versus other groups); **p < 0.005,
***p < 0.0001. PBMCs from healthy donors were cultured for 72 hr with
CHO-CD154 cells. PMA+iono were added for the last 6 hr of culture. Cells
were then stained with CD19, CD24, and CD38 mAbs and intracellularly
stained with IL-10 mAb or with an appropriate isotype control.
(D) IL-10 expression of CD19 gated cells.
(E) Overlays of CD19+IL-10+ B cells (black dots) on total CD19+ B cells
(gray dots) from one representative healthy donor.
(F) Histogram showing upregulation of CD154 expression on magnetic-bead-
sorted CD4+T cells after 6 hr of stimulation with 0.5 mg/ml plate-bound CD3
mAb (thick line) compared to unstimulated cells (dotted line).
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inhibited by the addition of blocking CD154 mAb.
CD19+CD24hiCD38hi B Cell Suppression Is Dependent
on IL-10, CD80, and CD86, but Not TGF-b
We next evaluated the potential effector mechanism(s) by which
CD19+CD24hiCD38hi B cells suppress cytokine production by
CD4+ T cells. CD4+CD25 T cells were cultured either alone or
1:1 with CD19+CD24hiCD38hi B cells in the presence of IL-10
and IL-10 receptor (IL-10R) mAbs, TGF-b, CD80, or CD86
mAbs. Inhibition of TGF-b during coculture had no impact on
the ability of CD19+CD24hiCD38hi B cells to suppress CD4+
T cell proinflammatory cytokine production. In contrast, blockade
of IL-10 restored TNF-a+CD4+ T cells to the frequencies observed
in cultures containing CD4+ T cells alone and also partially
restored IFN-g production by CD4+ T cells (Figures 3A and 3B;
cumulative results of this and additional results are shown as
bar charts on the right), suggesting that, similarly to the murine
experimental models of autoimmunity, additional interactions
are necessary for Breg cells to achieve their full suppressive
potential (Mann et al., 2007; Mizoguchi et al., 2000). Addition of
blocking antibodies against CD80, and to a lesser extent against
CD86, inhibited CD19+CD24hiCD38hi B cells from suppressing
the frequency of TNF-a+ and IFN-g+ CD4+ T cells (Figures 3A
and 3B). Although blockade of IL-10 and IL-10R, CD80, or
CD86 individually appeared to completely reverse the ability
of CD19+CD24hiCD38hi B cells to suppress the expression of
TNF-a by CD4+ T cells, the blockade of these molecules individ-
ually was not sufficient to reverse the suppression of IFN-g.
However, a combination of mAbs against all of three molecules
completely reversed the inhibition of IFN-g expression by CD4+
T cells. Thus, analogous to murine experimental models, the
suppressive effect of human Breg cells involves both the release
of IL-10 and CD80 and CD86 costimulatory signaling.
CD19+CD24hiCD38hi B Cells Isolated from SLE Patients
Do Not Suppress CD4+T Cell Cytokine Production
We next assessed whether the activity of Breg cells might be
altered in human autoimmune disorders. As a first B cell candi-
date disorder, we evaluated patients with active SLE. Because
of the difficulties of obtaining sufficient CD19+CD24hiCD38hi B
cell numbers from PB samples from SLE patients, we evaluated
whether depletion of CD19+CD24hiCD38hi from PBMCs derived
from healthy donors or patients with SLE might impact T cell
cytokine production. CD19+CD24hiCD38hi B cells were depleted
from the PBMCs of healthy donors and patients with SLE by flow
cytometry sorting. Undepleted PBMCs and PBMCs depleted
of CD19+CD24hiCD38hi B cells were then stimulated for 72 hr
with plate-bound CD3 mAb. We observed a significant
increase in the frequency of CD4+IFN-g+ and CD4+TNF-a+
T cells in CD19+CD24hiCD38hi B cell-depleted compared with
nondepleted PBMCs from healthy donors. The frequencies of(G) CD154 signals provided by CD4+T cells are required for the differentiation of
IL-10-producing B cells. Magnetic-bead-sorted CD4+ CD25T cells were culture
with flow cytometry-sorted CD19+CD38hiCD24hi B cells for 72 hr with 0.5 mg/ml
plate-bound CD3 mAb and isotype control or with CD3 mAb and blocking
CD154 mAb. Intracellular cytokine staining showing the effect that blocking
CD154 mAb has on the frequency of IL-10+CD19+ B cells. Data show the
responses of three individuals. The experiment was performed three times.
Figure 3. CD19+CD24hiCD38hi B Cell Suppression Depends Partially on the Release of IL-10, and CD80 and CD86 Engagement, but Is
TGF-b Independent
Negatively magnetic-bead-purified CD4+CD25 T cells were cultured with flow cytometry-sorted CD19+CD24hiCD38hi B cells, stimulated with 0.5 mg/ml
plate-bound CD3 mAb in the presence of blocking antibodies to IL-10 and IL-10R, TGF-b, CD80, or CD86 or with their matching irrelevant isotype control
(data not shown) (10 mg/ml of IL-10 and IL-10R mAbs; 2 mg/ml of TGFb mAb, 10 mg/ml of CD86 mAb, 10 mg/ml of CD80 mAb). PMA+iono were added for the
last 6 hr of culture. Cells were surface stained for the expression of CD4 and intracellularly stained for IFN-g and TNF-a. Expression of TNF-a and IFN-g was
assessed relative to isotype-matched control mAbs. Flow cytometry plots of (A) TNF-a and (B) IFN-g expression by CD4+T cells cultured alone or in the presence
of CD19+CD24hiCD38hi B cells and indicated blocking antibodies are representative of two separate experiments each with three individuals. The chart bar on the
right shows cumulative data as mean ± SE of three independent experiments. The results were compared with two-tailed t test analysis (isotype versus other
groups); **p < 0.005, ***p < 0.0001.
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of either CD19+CD24hiCD38 or CD19+CD24intCD38int B cells
were not increased compared to undepleted PBMCs (Figure S4).
In contrast to healthy donor PBMCs, depletion of CD19+
CD38hiCD24hi B cells from the PBMCs of SLE patients did not
lead to any significant increase in the percentages of CD4+
IFN-g+ or CD4+TNF-a+ T cells (Figures 4A and 4B). Our finding
using healthy donors provides further support for a direct role
for PB-derived CD19+CD24hiCD38hi cells in modulating T cell
inflammatory responses. Our data also indicate that the equiva-lent cell population in patients with SLE lacks a similar degree of
suppressive capacity. The inability of CD19+CD24hiCD38hi B
cells to suppress CD4+ T cell cytokine production observed in
the PBMCs of patients with SLE was not observed with samples
from patients with other arthritic diseases (OAD) such as Sjo¨g-
ren’s syndrome or osteoarthritis. Coculture of CD19+CD24hi
CD38hi B cells isolated from the PB of Sjo¨gren’s or osteoarthritis
patients with autologous CD4+ T cells led to a significant
decrease in the frequency of CD4+IFN-g+ and CD4+TNF-a+
T cells compared to CD4+ T cells cultured alone (Figures S5AImmunity 32, 129–140, January 29, 2010 ª2010 Elsevier Inc. 133
Figure 4. CD19+CD24hiCD38hi B Cells from SLE Patients Fail to
Suppress IFN-g+ and TNF-a+CD4+ T Cell Differentiation
PBMCs isolated from patients with SLE or healthy controls were stained with
CD19, CD24, and CD38 and DAPI and gated as shown in Figure 1A.
CD19+CD38hiCD24hi B cells were depleted, by flow cytometry sorting, from
whole PBMCs and the remaining live DAPI PBMCs were collected. Unde-
pleted DAPI PBMCs were also collected as a control. Cells were then
cultured for 72 hr with 0.5 mg/ml plate-bound CD3 mAb. PMA+iono was added
for the last 6 hr of culture. Depleted and nondepleted PBMCs were surface
stained with CD4 and CD19 mAbs, permeabilized, and stained with TNF-a
or IFN-g mAbs.
(A) Representative flow cytometry plots for CD4+IFN-g+ and CD4+TNF-a+
T cell.
(B) Graphs showing the differences in the frequency of IFN-g+CD4+ and
TNF-a+CD4+ T cells between depleted and nondepleted PBMCs from the
same individual. Healthy individuals are represented in black and SLE is
represented in white. Results from three healthy individuals and three SLE
patients are shown. The data are representative of four separate experiments.
p values for differences in cytokine production in healthy comparing pre- and
post-B cell depletion were calculated by two-tailed t test; **p < 0.01.
(C) Healthy CD19+CD24hiCD38hi B cells suppress SLE CD4+ T cells.
CD19+CD24hiCD38hi B cells were purified by flow cytometry from the PB of
healthy individuals and cultured 1:1 with either autologous magnetic-bead
purified CD4+CD25 T cells and autologous irradiated accessory cells or
with CD4+ T cells and irradiated accessory cells isolated from patients with
SLE in the presence of 0.5 mg/ml plate-bound CD3 mAb (1:10 irradiated
PBMCs:CD4+ T cells). PMA+iono was added for the last 6 hr of culture. Cells
were stained for the expression of CD4 and intracellularly for IFN-g and TNF-a.
Expression of IFN-g and TNF-a was assessed relative to isotype matched
control mAbs. The bar graph shows mean ± SE percentage inhibition of
IFN-g and TNF-a expression by CD4+ T cells after culture with CD19+CD24hi
CD38hi B cells compared to SLE CD4+ T cells cultured alone.
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cells isolated from OAD patients was comparable to the
suppressive capacity of CD19+CD24hiCD38hi B cells isolated
from healthy donors (Figures S5A and S5B). In addition,
CD19+CD24hiCD38hi B cells isolated from OAD patients produce
similar amounts of IL-10 compared to healthy
CD19+CD24hiCD38hi B cells, reinforcing the association
between B cell, IL-10 production, and suppressive capacity
(Figures S5C and S5D). Thus, the lack of suppressive effect of
SLE CD19+CD24hiCD38hi B cells does not simply reflect a feature
of all arthritic diseases but may be specific to SLE patients. The
lack of effect on T cell inflammatory cytokine production
observed after depletion of CD19+CD38hi
CD24hi B cells from the PBMCs of SLE patients could reflect
either: (1) a B cell-extrinsic deficit(s) specific to SLE derived
T cells, (2) numerical deficiency of the regulatory subset, and/
or (3) a B cell-intrinsic functional impairment within this regula-
tory subset. To address these possibilities, we first investigated
whether SLE effector T cells are resistant to the suppressive
effect exerted by regulatory CD19+CD24hiCD38hi B cells derived
from healthy donors. Flow cytometry-purified, CD19+
CD24hiCD38hi B cells from healthy donors were cultured with
either autologous CD4+ T cells or with CD4+ T cells isolated
from SLE patients. Healthy CD19+CD24hiCD38hi B cells were
able to suppress IFN-g and TNF-a expression by SLE CD4+
T cell almost as efficiently as they were able to suppress cytokine
expression by autologous healthy CD4+ T cells (Figure 4C).
Therefore, it is unlikely that the lack of suppression by SLE
CD19+CD24hiCD38hi B cells observed in Figure 4A reflects
intrinsic differences in effector T cell activity in SLE versus
control donors.
SLE Patients Display Similar Numbers
of CD19+CD38hiCD24hi B Cells Compared
with Healthy Individuals
We next evaluated whether there was a numerical deficit in
CD19+CD38hiCD24hi B cells in the PB of patients with SLE. The
relative percentages of CD19+CD38hiCD24hi, CD19+CD38
CD24hi, and CD19+CD38intCD24int B cell subsets were measured
in the PB of healthy individuals versus SLE patients or versus age-
matched control patients with OAD. As reported elsewhere, we
observed significantly higher percentages of CD19+CD38hiCD24hi
B cells in the PBMCs of patients with SLE compared to healthy
individuals or to patients with OAD (Figure 5A) (Sims et al., 2005).
However, the absolute cell numbers of CD19+CD38hiCD24hi B
cells/liter in the PB of controls versus patients with SLE were not
statistically different (Figure 5B). In contrast, the numbers of both
CD19+CD38intCD24int and CD19+CD24hiCD38 B cells were
both significantly reduced in SLE patients. These results suggest
that the inability of SLE CD19+CD38hiCD24hi B cells to suppress
the expression of proinflammatory cytokines by CD4+ T cells is
unlikely to be due to a numerical deficiency.
CD19+CD24hiCD38hi B Cells Are ‘‘Refractory’’
to CD40 Engagement
Next we evaluated whether CD19+CD38hiCD24hi B cells derived
from SLE patients might exhibit cell-intrinsic deficits in response
to CD40 stimulation followed by short period of PMA+iono
stimulation (stimuli that upregulate IL-10 expression by B cells
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observed a profound impairment in IL-10 production after cocul-
ture with CHO-CD154 cells followed by PMA+iono stimulation
(Figures 5C and 5D). In particular, whereas healthy CD19+
CD24hiCD38hi B cells responded to CD40 engagement, followed
by PMA+ion stimulation, by upregulating IL-10 production, SLE
CD19+CD24hiCD38hi B cells were refractory to the same combi-
nation of stimuli (Figures 5C and 5D). In contrast to the IL-10
production by SLE B cells after CD40 engagement, the levels
of IL-10 production upon CpG+PMA+ion stimulation were
restored to levels nearly equivalent to those observed in healthy
controls. Stimulation of rodent splenocytes or human PBMCs
with CPG was previously shown to upregulate the production
of IL-10 by B cells (Barr et al., 2007; Brummel and Lenert,
2005; Gantner et al., 2003). These findings show that, unlike
healthy CD19+CD24hiCD38hi B cells, CD19+CD24hiCD38hi
B cells isolated from SLE patients are unable to express IL-10
after activation via CD40, followed by PMA+iono stimulation
(Figure 5D). We also tested whether this deficit reflected a defect
in CD40 expression. CD40 was similarly expressed on B cells
derived from healthy and SLE patients, indicating that the lack
of IL-10 upregulation was not due simply to a decrease in
CD40 expression (data not shown).
Alteration of STAT3 Signaling after CD40 Engagement
of CD19+CD24hiCD38hi SLE B Cells
CD40 ligation results in the activation of multiple signaling
cascades. Among CD40-triggered signals, the JAK3 (Janus
family of kinases) and STAT3 (signal transducer and activators
of transcription family) cascade (Hanissian and Geha, 1997)
provides a pathway that can be measured with flow cytometry.
This provides a direct cell-based assessment of CD40-driven
biochemical events in the limited numbers of CD24hiCD38hi B
cells obtainable within peripheral blood samples. Therefore, we
investigated whether CD24hiCD38hi B cells, by virtue of their
ability to upregulate IL-10 upon CD40 engagement, might
display a different pattern of STAT3 phosporylation (p-STAT3)
compared to other B cell subsets. In vitro stimulation of PB
cells derived from healthy donors with an agonistic CD40 mAb
led to significantly higher (p < 0.05) p-STAT3 expression in
CD24hiCD38hi B cells compared with either CD24intCD38int or
CD24hiCD38 B cells (Figures 5E and 5F). No significant
increases in the phosphorylation of STAT3 in any SLE-derived
B cell subset were detected. Furthermore, we observed consis-
tently higher basal STAT3 phosphorylation (p < 0.05) in healthy
donor-derived versus SLE-derived CD24hiCD38hi B cells.
These findings clearly demonstrate that STAT3 is phosphory-
lated in CD24hiCD38hi B cells in response to CD40 ligation and
suggest that this and/or other CD40-dependent proximal signals
are impaired in CD24hiCD38hi B cells isolated from SLE patients.
Other downstream events of CD40 signaling, such as the upre-
gulation of the activation markers CD80 and CD86, did not
appear to be altered in CD19+CD24hiCD38hi B cells from SLE
patients (Figure S6).
DISCUSSION
The delicate balance between pathogen-induced effector func-
tions and endogenous tolerance-mediating mechanisms is ofvital importance to the integrity of a host in the course of an
immune response (Kyewski and Klein, 2006). So far maintenance
of this balance has been mainly attributed to regulatory T (Treg)
cells (Belkaid and Tarbell, 2009). Our results however, demon-
strate that human PB also contains a population of B cells with
regulatory capacity. CD19+CD24hiCD38hi B cells significantly
inhibit the differentiation of proinflammatory cytokine expressing
CD4+ T cells in a dose- and contact-dependent manner.
Human PB CD19+CD24hiCD38hi B cells have previously been
identified as immature transitional B cells (Palanichamy et al.,
2009; Sims et al., 2005) (Plebani et al., 2007). Here, we have
ascribed these cells with a regulatory capacity. We propose
that within the subset of PB B cells with a CD19+CD24hiCD38hi
phenotype, there are both functionally immature transitional B
cells and B cells that are functionally regulatory. Whether these
functions are shared by ontologically different B cell subsets is
yet to be established. It is therefore possible that the observed
T cell suppression is the consequence of a developmentally
regulated response of CD19+CD24hiCD38hi B cells to CD40
engagement (Masood et al., 1995; Rousset et al., 1992).
However, we cannot exclude the possibility that PB
CD19+CD24hiCD38hi B cells are comprised of two functionally
and even developmentally distinct subpopulations: ‘‘conven-
tional’’ CD19+CD24hiCD38hi immature B cells programmed to
become mature B cells and CD19+CD24hiCD38hi-like regulatory
B cells.
As with regulatory T cells, there may be a number of distinct
regulatory B cell subsets. We have found that although defining
regulatory B cells with a CD19+CD24hiCD38hi phenotype
enriches for a population of IL-10+ regulatory B cells, other B
cell subsets, such as CD19+CD24intCD38int B cells, in the periph-
eral blood also express IL-10. Our results suggest that, in
addition to IL-10 production, other soluble factors or costimula-
tory molecules that might be present specifically on the
CD24hiCD38hi B cell subset could be required for suppression.
It remains to be formally proven whether the IL-10-producing B
cells contained within these other B cell subsets are functionally
suppressive. At present we have no means of purifying exclu-
sively those B cells that express IL-10 in sufficient quantities to
perform functional studies. It is therefore important to continue
to address the existence of potential additional regulatory B
cell subsets, given that they might play a role in the maintenance
of the balance between tolerance and autoimmunity.
Despite phenotypic and functional similarities, our studies
revealed several key differences between murine and human
regulatory B cells. The suppressive activity of murine Breg cells
is primarily, if not exclusively, IL-10 dependent (Bouaziz et al.,
2008; Mauri and Ehrenstein, 2008; Mizoguchi and Bhan, 2006).
In contrast, whereas neutralization of IL-10 in human B cell and
T cell cocultures completely restored TNF-a production by target
CD4+ T cells, IL-10 inhibition alone did not fully restore T cell
IFN-g production. In addition, whereas in mice TGF-b has been
shown to mediate Breg cell-suppressive activity in experimental
diabetes (Tian et al., 2001), human CD19+CD24hiCD38hi B cell-
suppressive capacity is not dependent on TGF-b production.
An important feature of the suppressive capacity of human
CD19+CD24hiCD38hi B cell is the involvement of CD80 and
CD86. In a TCRa KO mouse model of intestinal inflammation,
CD86 in particular has been reported to mediate the suppressiveImmunity 32, 129–140, January 29, 2010 ª2010 Elsevier Inc. 135
Figure 5. CD19+CD24hiCD38hi B Cells from SLE Patients Express Lower Amounts of IL-10 and Lower Amounts of Phosphorylated STAT-3 in
Response to CD40 Followed by PMA+iono Stimulation, Compared to Healthy Controls
PBMCs isolated from patients with SLE and healthy controls were stained directly ex vivo for the expression of CD19, CD24, and CD38.
(A) Representative flow cytometry plot of B cell subset gating for a SLE sample showing CD19+CD24hiCD38hi, CD19+CD24intCD38int, and CD19+CD24hiCD38
B cells. Scatter plots show mean percentages of B cells within each subset in the peripheral blood of 14 healthy individuals and 25 patients with active SLE
(for information about clinical status of SLE patients, refer to Table 1). p values were calculated by two-tailed t test; **p < 0.01.
(B) Bar charts showing the mean absolute numbers ± SE (cells/liter of blood) of B cells within each subset for the same individuals and patients; *p < 0.05. IL-10
expression by healthy versus SLE B cell subsets is shown. PBMCs from healthy individuals and patients with SLE were stimulated for 72 hr with CHO-CD154
cells, control CHO cells, or CpG (0.1 mM). PMA+iono were added for the last 6 hr of culture. Cells were surface stained with CD19, CD24, and CD38 mAbs
and intracellularly stained for IL-10. Expression of IL-10 was assessed relative to isotype matched control mAbs. B cell subsets were gated as in (A).
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Moreover, it has been shown that blockade of CD80 impairs
Treg cell-suppressive capacity (Hajoui et al., 2004). Our results
suggest that CD80 and CD86 interactions between B cells and
CD4+ T cells work synergistically with B cell IL-10 production to
suppress CD4+ T cell cytokine production. CD28 and CTLA-4,
both expressed by a variety of T cell populations, including regu-
latory T cells, are both ligands for CD80 and CD86 (Salomon and
Bluestone, 2001; Tang and Bluestone, 2008). A previous study
revealed that CD80 expressed on DCs acts preferentially as
a ligand for CTLA-4 and mediates Treg cell suppression (Zheng
et al., 2004). However, whether this exact mechanism is utilized
by Breg cells will be subject for future investigations.
Defects in regulatory T cells have been identified in several
autoimmune diseases including rheumatoid arthritis (RA),
multiple sclerosis (MS), and SLE (Ehrenstein et al., 2004; Viglietta
et al., 2004). Here, we propose that regulatory B cells may also
be defective in SLE patients. Because of the profound lympho-
penia that characterizes the majority of patients with SLE, and
the small volumes of SLE PB available from active patients, we
have not been able to directly test the suppressive capacity of
purified CD19+CD24hiCD38hi B cells derived from SLE patients
(using coculture assays with CD4+T cells). Nevertheless, our
data clearly show that depletion of CD19+CD24hiCD38hi B cells
from the PBMCs of SLE patients fails to promote an increase
in CD4+ T cell inflammatory cytokine production as it does in
healthy controls or patients with OAD. Our results with SLE
T cells contrast with previous reports indicating that effector
T cells in SLE patients are refractory to Treg cell suppression
(Vargas-Rojas et al., 2008). This may be due to the different
stimuli used to activate effector cells (CD3 mAb and irradiated
PBMCs in our study versus CD3 mAb and CD28 mAb in previous
studies), as well as differences in treatment regimes. Our data
showing that healthy CD19+CD24hiCD38hi B cells were capable
of efficiently suppressing cytokine production by SLE effector
CD4+ T cells indicates that an alteration in T cell resistance
in SLE is unlikely to explain the failed response to CD19+
CD24hiCD38hi B cell depletion in our assays.
B cells in patients with SLE display a variety of abnormalities
including abnormal expression or function of key signaling mole-
cules, costimulatory pathways, cytokines, and perturbations in
developmental subsets (Grammer and Lipsky, 2003). Here, we
report an additional defect in SLE patients associated with
CD40 signaling cascades in CD19+CD24hiCD38hi B cells. Unlike
healthy B cells, CD19+CD24hiCD38hi B cells from SLE patients
display impaired IL-10 production when activated via CD40.
This deficit correlated with lower levels of STAT-3 phosphoryla-
tion. However, upregulation of CD80 and CD86 in response to(C) Representative dot plot showing the frequency of CD19+CD24hiCD38hi, CD19
one SLE patient.
(D) Cumulative results from three independent experiments with five samples pe
marked subsets upon different stimulation. IL-10 signaling response upon CD40
lated STAT-3 phosphorylation by SLE and healthy B cell subsets. B cell subset k
STAT-3 phosphorylation by flow cytometry after stimulating PBMC from health
(0.5 mg/106 cells). Cells were surface stained with CD19, CD24, and CD38 mAbs
(E) STAT-3 phosphorylation at 5 min post stimulation with CD40 mAb is depicte
compared to the unstimulated control at time zero. Difference between pairs wa
(F) Representative histograms of pSTAT-3 expression by CD19+CD24hiCD38hi, C
ulation with CD40 mAb for one SLE patient and one healthy control.CD40 stimulation did not appear to be altered in CD19+
CD24hiCD38hi B cells from SLE patients. This suggests that the
defective response to CD40 signaling in these cells may be
limited to certain cellular functions, in particular Stat-3 phos-
phorylation and IL-10 production. Previous studies have re-
ported an increase in CD154 expression on SLE T cells (Koshy
et al., 1996). It is conceivable that this change might result in
the overstimulation of SLE Breg cells, perhaps rendering them
less capable of an appropriate IL-10 response upon CD40
engagement, followed by PMA+iono stimulation, in a context
where they would otherwise have a regulatory function. Our
results also shed further light on previous data showing that
the strength of CD40 stimulation may dictate the direction (acti-
vation versus inhibition) of B cell responses (Mathur et al., 2004;
Miyashita et al., 1997).
Our combined studies provide important new data defining the
phenotype and suppressive activity for a potential regulatory B
cell population in healthy humans and for a defect in the activity
of such cells in an autoimmune disease setting. At present, our
data are insufficient to determine whether the defective
response to CD40 stimulation in CD19+CD24hiCD38hi SLE B
cells and the failed suppressive capacity of this population
reflects an initiating, as opposed to a secondary, effect of SLE
disease processes. Ongoing studies designed to test whether
regulatory B cell function can be restored after B cell depletion
therapy in SLE may help to address this question. In association
with previous reports showing defects in Treg cell activity in SLE,
our data suggests that a broad range of deficiencies in immune
regulatory cell function may be present in this and, possibly,
other autoimmune diseases.
EXPERIMENTAL PROCEDURES
Patients and Controls
SLE patients fulfilling the American College of Rheumatology revised classifi-
cation criteria for lupus (Tan et al., 1982) were assessed for disease activity
with the British Isles Lupus Assessment Group index (Hay et al., 1993). Only
patients with active SLE (British Isles Lupus Assessment global score higher
than 4) were included (mean age, 39 years; age range, 19–76 years). Table 1
summarizes the characteristics of patients with SLE. Healthy individuals
(mean age, 38 years; age range, 24–64 years) were studied in parallel as
controls. Age-matched patients with Sjo¨gren’s syndrome disease and patients
with osteoarthritis (mean age 65) were included in this study as disease control
(OAD). The ethics committee of the University College London Hospitals
National Health Service Trust approved this study; patients and healthy volun-
teers were recruited after obtaining informed consent.
Human Cell Isolation
PBMCs were isolated by Ficoll-Paque Plus (Amersham Biosciences, Uppsala,
Sweden) gradient centrifugation. Isolated PBMCs were resuspended in FCS+CD24intCD38int, and CD19+CD24+CD38 B cells positive for IL-10 staining in
r group. Bar charts represent mean ± SE percentages of IL-10+ B cells within
engagement is altered in SLE CD19+CD24hiCD38hi B cells. CD40 mAb stimu-
inase activity in response to CD40 ligation was assessed by measurement of
y controls (n = 6) and SLE patients (n = 6) in vitro with agonistic CD40 mAb
.
d. Phosphorylation is plotted as mean percentage increase ± SE in pSTAT-3
s evaluated by two-way ANOVA; * p <0.05.
D19+CD24intCD38int, and CD19+CD24+CD38 B cells at 0 and 5 min poststim-
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Table 1. Summary of SLE Patient Clinical Data
Subject Gender Symptoms Therapies BILAG C3, g/l dsDNA, IU/ml Anti-ENA
1 F f, a, obs nt 13 0.89 295 negative
2 F a, ser, sv hcq, mtx, 15 0.88 244 negative
3 F a, ser, lym pred, hcq, mtx, aza, 14 0.95 570 Ro, RNP
4 F a, ser, n, sv n.t 12 0.15 352 Sm, RNP
5 F a, ser, n, sv pred, hcq, aza, mmf 26 0.5 2866 RNP
6 F a, ser, n, sr pred, hcq, aza, 13 0.64 2560 RNP
7 F a, ser, n, sv pred, hcq, mtx, aza, 24 0.83 3879 Ro, La, RNP
8 F at, h, an, n pred, hcq, aza, mmf, 16 0.4 510 negative
9 M a, ser, n pred, aza, 11 0.52 218 Ro, La, RNP
10 F a, ser, sr n.t 14 0.53 39 Sm, RNP
11 F f, sr, s, n pred, aza, cyc, cya, mmf 12 0.44 13 Ro
12 F a, n. pred, hcq, 12 0.88 118 Ro, Sm, RNP
13 F f, a, n n.t. 20 0.65 10 negative
14 F at pred, hcq, aza 3 1.34 21 negative
15 F f, a, vas, n pred, aza, mmf 19 0.21 1364 negative
16 M h, a, n pred, aza, 12 0.81 15 negative
17 F n pred, aza, mmf 6 0.89 203 negative
18 F a, n pred, aza, mmf 17 0.35 522 Ro, Sm, RNP
19 F f, a, n, sr pred, hcq, aza, mmf 8 0.68 267 Ro
20 F a, s, n hcq, aza, mmf 6 1.15 124 Ro, La, Sm, RNP
21 F a. hcq, mtx, aza, 12 1.39 10 Ro
22 F a, n hcq, aza, 12 0.61 1058 Sm, RNP
23 F f, a, n, obs nt 45 0.42 4386 Ro, Sm, RNP
24 F f, a, s, sv hcq, mtx, aza, 13 1.5 31 RNP
The following abbreviations are used: arthritis (a), serositis (ser), skin vasculitis (sv), lymphadenopathy (lym), skin rash (sr), hemolytic (h), anemia (an),
nephritis (n), fever (f), organic brain syndrome (obs), autoimmune thrombocytopaenia (at), predinsolone (pred), hydroxychloroquine (hcq), methotrexate
(mtx), azathioprine (aza), mycophenolate (mmf), and not treated (nt).
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freezing. B cell subsets, CD4+CD25 T cells, and PBMCs depleted of B cell
subsets were isolated by FACSAria (Becton Dickinson, Franklin Lakes, USA)
on the basis of their expression of CD4 or CD19, CD24, and CD38 and DAPI
(BD Biosciences, San Jose´, USA). Untouched CD4+CD25 T cells were also
isolated by magnetic-bead purification with MACS kits (Miltenyi, Bergisch
Gladbach, Germany). Absolute numbers of cells within each B cell subset/liter
were calculated for healthy controls by multiplying 103 the total number of
lymphocytes isolated/100 ml blood by the fraction of PBMCs contained within
each subset as determined by flow cytometry. SLE patient B cell subset
numbers were determined by multiplying clinical lymphocyte counts by the
fraction of PBMCs contained within each subset.
Cell Culture
Human cells were cultured in RPMI 1640 containing L-glutamine and NaHCO3
(Sigma-Aldrich, St. Louis, USA) supplemented with, 100 U/mg/ml penicillin/
streptomycin (Life Technologies, Carlsbad, USA), and 10% FCS (Biosera,
Ringmer, UK) in 96-well U-bottom plates (Nunc, Langenselbold, Germany).
CD154 expressing, and untransfected control Chinese hamster ovary (CHO)
cells (kindly provided by Prof R. Mageed, Queen Mary’s, University of London,
UK) were grown in DMEM containing 4500 mg/L glucose, 110 mg/L sodium
pyruvate and L-glutamine (Sigma-Aldrich) with 100 U/ml penicillin and
streptomycin and 5% FCS. CD154 expression was routinely checked by
flow cytometry analysis after staining with CD154-PE mAb. For coculture
experiments, CHO cells were first X-ray irradiated (240kV, 10 mA, 10.19
mGy/s) in 25 cm2 cell culture flasks for 99.9 min then cultured with human
PBMCs at a ratio of 1:10 CHO:PBMC. For experiments with purified SLE
CD4+ T cells, autologous irradiated PBMCs (40 Gy dose), depleted of CD4+138 Immunity 32, 129–140, January 29, 2010 ª2010 Elsevier Inc.T cells by magnetic-bead purification, were added at a ratio of 1:10 irradiated
PBMCs:CD4+ T cells.
Cytokine Detection
For analysis of human intracellular cytokine production, PBMCs were stimu-
lated with either 0.5 mg/ml purified plate-bound CD3 mAb (Hit-3a) (BD Biosci-
ences) for 3 days for T cell cocultures, or with CD154 expressing CHO cells
(1:10 CHO:B cells or PBMCs) or 0.1 mg/ml CpG ODN2006 (Invivogen, San
Diego, USA) for 72 hr for B cells. GolgiPlug (BD Biosciences) was added for
the last 6 hr along with PMA+iono. For intracellular staining, cells were stained
with combinations of CD4-Alexa Fluor488, CD19-PE-Cy7, CD38-FITC, CD38-
PE-Cy5, CD24-PE, CD24-biotin, and CD24-FITC mAbs (BD Biosciences).
Cells were washed, fixed, permeabilized, and stained for detection of intracel-
lular cytokines with IFN-g-APC, TNFa-APC, and IL-10-APC mAbs (BD Biosci-
ences). Appropriate APC-conjugated isotype controls were used for gate
setting for cytokine expression. Alternatively, IL-10 was measured in the
culture supernatants by ELISA (BD Biosciences) with aliquots of supernatant
taken from cell cultures before the addition of GolgiPlug and PMA+iono to
the cultures.
Cell Signaling
PBMCs were rested for 1 hr in medium. Cells were then stimulated by incuba-
tion with 5 mg/ml purified stimulatory mouse-anti-human CD40 mAb (clone-
5C3, BD Biosciences) (0.5 mg CD40 mAb/106cells) for 30 min on ice in the
dark. Cells were washed with ice-cold PBS, 5 mg/ml goat anti-mouse IgG
F(ab’)2 was added, and finally the cells were incubated at 4
C for 20 min. Cells
were stained with appropriate antibodies for 30 min in ice-cold PBS at 4C.
Cells were washed with ice-cold PBS, resuspended in warm PBS, and
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Phosflow antibody (BD Biosciences) was used at a 1:50 dilution of stock in
Permwash (BD Biosciences) with 50 ml/well.
B Cell Functional Assays
Cocultures of 2.5 3 105 B cells and 2.5 3 105 CD4+ CD25 T cells (1:1) were
stimulated with plate-bound CD3 mAb (0.5 mg/ml) for 72 hr. GolgiPlug (BD
Biosciences) was added for the last 6 hr along with PMA+iono. Cells were
surfaced stained, permeabilized, stained intracellularly for IFN-g and TNF-a,
and analyzed by flow cytometry. For experiments with purified SLE CD4+
T cells, autologous irradiated PBMCs (40 Gy dose), depleted of CD4+ T cells
by magnetic-bead purification, were also added at a ratio of 1:10 irradiated
PBMCs:CD4+ T cells.
Statistics
All values are expressed as mean ± SEM. We performed analysis of signifi-
cance in Prism (GraphPad, La Jolla, USA) by the two-tailed t test analysis
and by two-way ANOVA.
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